The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety of preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: An interim safety analysis from the phase III PREVENT trial of the AIO/CAOGI/ACO.
 
Thorsten Goetze
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Foundation Medicine; Incyte; Lilly; MSD Oncology; Novartis; Roche; SERVIER
Speakers' Bureau - Lilly; MSD Oncology
Research Funding - AstraZeneca (Inst); Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe (Inst); Gemeinsamer Bundesausschuss; Incyte (Inst); Lilly (Inst)
 
Pompiliu Piso
No Relationships to Disclose
 
Ulli Simone Bankstahl
No Relationships to Disclose
 
Claudia Pauligk
No Relationships to Disclose
 
Claudia Volk
No Relationships to Disclose
 
Fabienne Knapp
No Relationships to Disclose
 
Disorn Sookthai
Stock and Other Ownership Interests - Bayer; Fresenius Kabi
 
Sylvie Lorenzen
Consulting or Advisory Role - BMS GmbH & Co. KG; Lilly; MSD
 
Michael Schenk
No Relationships to Disclose
 
Armin Wiegering
No Relationships to Disclose
 
Peter Jo
No Relationships to Disclose
 
Jens Werner
No Relationships to Disclose
 
Jens Peter Hölzen
No Relationships to Disclose
 
Daniel E Stange
Patents, Royalties, Other Intellectual Property - Patent pending for FLOT chemotherapy testing using organoids. Patent registration number #10 2022 132 767.1. Patent title: "Verfahren zur Prädiktion eines patientenindividuellen Ansprechen auf das FLOT-Chemotherapie-Schema".
 
Alexander Stein
Consulting or Advisory Role - Amgen (Inst); AstraZeneca; Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); Merck KGaA; MSD (Inst); Novartis (Inst); Pierre Fabre (Inst); Pierre Fabre (Inst); Roche; SERVIER (Inst); Taiho Oncology (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); Daiichi Sankyo Europe GmbH (Inst); Merck KGaA; Seagen (Inst); Servier
Research Funding - Bristol-Myers Squibb (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pierre Fabre (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo Europe GmbH
 
Harald Schmalenberg
Consulting or Advisory Role - Lilly; Merck; MSD
 
Metin Senkal
No Relationships to Disclose
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - Immutep; Institut für Klinische Krebsforschung GmbH
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; Eli Lilly Germany; Merck Sharp & Dohme
Speakers' Bureau - AIO gGmbH; Bristol-Myers Squibb; Lilly; MCI Group
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Eurozyto; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Immutep; Ipsen; Lilly; MSD Sharp & Dohme; Roche; Sanofi; Vifor Pharma